The angel investor network of Boğaziçi University, BUBA Ventures, has acquired Hasbiotech Pharmaceutical Industry and Commerce Corporation, which focuses on innovative treatments in medicine. Having come to the fore with its investments in ventures such as FlyMedi and NetworkDry to date, BUBA Ventures has made an important investment in the health sector.
BUBA Ventures has announced that it acquired Hasbiotech Pharmaceutical Company, which develops original product development projects in medicine in Turkey and worldwide. Besides developing products, Hasbiotech also offers the innovative medical products of Cuba in the Turkish market since 2014.
Hasbiotech, which introduced an innovative and original product that prevents amputation in diabetic foot ulcer to the Turkish pharmaceuticals industry, thereby offering a solution to a great need, continued to bring in Cuban technologies with new products in 2015 to Turkey.
The company, founded in 2009, also run projects to develop original products together with Cuba. In this context, we can state that Hasbiotech, which offers solutions especially in oncology, draws attention with its original products. The company manifested its success in the sector by bringing a very important product that is effective on lung cancer in 2018.
In addition to these, let us note that Hasbiotech offers the innovative products of Biocuba Pharma, a leading technological base in the world, to the Turkish market. The company initiated its original product development investments backed by the Ministry of Health in 2016. Hasbiotech continues to make important investments in medications that will introduce innovative solutions in diseases like heart attack and Alzheimer's disease.
In his statement, the Chairman of BUBA Ventures Timuçin Bilgör said the following:
In acquiring Hasbiotech, an important player in the field of health services in Turkey, we aim to support solutions to the needs of the Turkish healthcare sector, innovative and pioneering treatments, and the success of Turkey in the field of healthcare. Furthermore, we will serve as a vital bridge in the development and marketing of Cuban technologies